
Supplementary Table 1. Reporting recommendations for tumour marker prognostic studies (REMARK)


Items	/								Authors		
	Bagno	Calur	Ca	Elgaae	Ga	Hu	Kapetanak	Le	Leskelä	Marchi	Мє
	li	a	0	n	0		is	e		ni	
Introduction	1		1	1	1	1		ı	ı	ı	,
1.objectives and	$\sqrt{}$		V	V		$\sqrt{}$		V	$\sqrt{}$	$\sqrt{}$	V
hypotheses											
Materials and Met	noas										
Patients	1	I	1	1	1	1	1	1	ı	I	,
2.characteristics	<b>V</b>	V	V	V	V	V	V	V	V	$\sqrt{}$	V
3.treatment methods	V										
Specimen characte	rictics										
4.biological	11811CS √			$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	V	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$
material	•	٧	•	•	•	•	•	•	٧	٧	٧
Assay methods											
5. method protocol	$\sqrt{}$			$\sqrt{}$			$\sqrt{}$		$\sqrt{}$	$\sqrt{}$	$\sqrt{}$
Study design											
6.method of case	$\sqrt{}$	$\sqrt{}$		$\sqrt{}$			$\sqrt{}$		$\sqrt{}$	$\sqrt{}$	$\sqrt{}$
selection			,		,	,	,	,		,	,
7.define clinical	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$
and points											
examined	. 1										
8.candidate variable	V										
9.sample size	2	$\sqrt{}$	2/	al.	$\sqrt{}$	2/	2	2/	N	N.	٦/
Statistical analysis	methods	'	V	V	V	V	V	V	V	V	٧
10.statistical	V	, √		$\sqrt{}$			$\sqrt{}$		$\sqrt{}$	$\sqrt{}$	$\sqrt{}$
methods	·	•	,	,	,	·	,	,	·	·	·
11.cutpoint	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$		$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$
Results											
Data		,	,		,	,	,	,		,	,
12.number of	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$
patients	1	I	1	1	1	1	ı	1	ı	I	,
13.demographic	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	V	V	$\sqrt{}$	$\sqrt{}$	V
characteristics	4-4 <b>:</b>										
<b>Analysis and prese</b> 14. the relation of	ntation √	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$		$\sqrt{}$		$\sqrt{}$	$\sqrt{}$	N
the marker to	V	V	V	V	V	V	V	V	V	V	٧
standard											
prognostic											
variables											
15.univariate	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\checkmark$		$\sqrt{}$	$\sqrt{}$	$\sqrt{}$
analyses											
16.multivariable	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$				$\sqrt{}$			$\sqrt{}$	$\sqrt{}$


analyses 17. effects and confidence	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$		$\sqrt{}$		$\sqrt{}$	<b>V</b>	$\checkmark$	$\checkmark$	$\sqrt{}$
intervals 18.further investigations						$\sqrt{}$					$\sqrt{}$
Discussion											
19.interpret the	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$								
results											
20.implications for future research	$\sqrt{}$	$\sqrt{}$		$\sqrt{}$	$\sqrt{}$			$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$

Supplementary Figure 1. Forest plot showing the combined HR from included studies for the association between the expression levels of miR-200 family and OS. OS = overall survival.




## Supplementary Figure 2. Sensitivity analyses of studies regarding miR-200 family expression and OS. OS = overall survival.







**Supplementary Figure 3. Begg's funnel plot of standard error for assessing publication bias.** A, miR-200a. B, miR-200b. C, miR-200c. D, miR-141.


(B)






## (C)






**Supplementary Figure 3. Begg's funnel plot of standard error for assessing publication bias.** A, miR-200a. B, miR-200b. C, miR-200c. D, miR-141.

Supplementary Figure 4. Forest plots of subgroup analysis by study samples regarding the miR-200 family expression and OS of patients with ovarian cancer. A, the study samples were tissues. B, the study samples were blood. (A)




(B)




Supplementary Figure 4. Forest plots of subgroup analysis by study samples regarding the miR-200 family expression and OS of patients with ovarian cancer. A, the study samples were tissues. B, the study samples were blood.

Supplementary Figure 5. Forest plots of subgroup analysis by study kinds regarding the miR-200 family expression and OS of patients with ovarian cancer. A, the study kinds were multivariate study. B, the study kinds were univariate study. C, divided miR-200 family into two clusters based on chromosomal location. OS overall survival. (A)




(B)



Supplementary Figure 5. Forest plots of subgroup analysis by study kinds regarding the miR-200 family expression and OS of patients with ovarian cancer. A, the study kinds were multivariate study. B, the study kinds were univariate study. C, divided miR-200 family into two clusters based on chromosomal location. OS = overall survival.

(C)



Supplementary Figure 6. Forest plot showing the combined HR from included studies for the association between the expression levels of miR-200 family and PFS. PFS = progression free survival.

